Sitagliptin (DPP-4 inhibitor)

•  Approved by the US Food and Drug Administration (FDA) for use with diet and exercise to Improve glycemic control in adult patients with type 2 diabetes,
• Sitagliptin is a highly selective DPP-4 inhibitor that has been approved for type 2 diabetes therapy. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion.

Metformin

• It is a biguanide that decreases blood glucose concentration by mechanisms different from those of insulin secretagogues, such as sulfonylurea, or exogenous insulin therapy.
• Unlike the sulphonylureas, metformin does not cause hypoglycemia, it is an effective antihyperglycemic agent which appears to improve aberrant plasma lipid and fibrinolytic profiles associated with non-insulin-dependent diabetes mellitus.